Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Table of Contents

February 01, 1995; Volume 23,Issue 2
  • You have access
    Relevance of tissue distribution studies.
    K Yeleswaram
    Drug Metabolism and Disposition February 1995, 23 (2) 159;
  • You have access
    Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes.
    P Moroni, T Buronfosse, C Longin-Sauvageon, P Delatour and E Benoit
    Drug Metabolism and Disposition February 1995, 23 (2) 160-165;
  • You have access
    Kinetics of sequential metabolism. Contribution of parallel, primary metabolic pathways to the formation of a common, secondary metabolite.
    K S Pang
    Drug Metabolism and Disposition February 1995, 23 (2) 166-177;
  • You have access
    Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II).
    M Jennerwein and P A Andrews
    Drug Metabolism and Disposition February 1995, 23 (2) 178-184;
  • You have access
    Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors.
    S K Balani, S M Pitzenberger, M S Schwartz, H G Ramjit and W J Thompson
    Drug Metabolism and Disposition February 1995, 23 (2) 185-189;
  • You have access
    Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
    J A Ring, H Ghabrial, M S Ching, A Shulkes, R A Smallwood and D J Morgan
    Drug Metabolism and Disposition February 1995, 23 (2) 190-196;
  • You have access
    Disposition of ciprofloxacin in the isolated perfused rat liver.
    A R Abadìa, L De Francesco and A Guaitani
    Drug Metabolism and Disposition February 1995, 23 (2) 197-200;
  • You have access
    Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat.
    A Hiratsuka, T Y Chu, E W Distefano, L Y Lin, D A Schmitz and A K Cho
    Drug Metabolism and Disposition February 1995, 23 (2) 201-206;
  • You have access
    Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.
    R A Stearns, P K Chakravarty, R Chen and S H Chiu
    Drug Metabolism and Disposition February 1995, 23 (2) 207-215;
  • You have access
    Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog.
    L E Van Beijsterveldt, R J Geerts, K Wuyts, R J Woestenborghs, W E Meuldermans and J J Heykants
    Drug Metabolism and Disposition February 1995, 23 (2) 216-222;
  • You have access
    Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice.
    A M Cheraghali, R Kumar, E E Knaus and L I Wiebe
    Drug Metabolism and Disposition February 1995, 23 (2) 223-226;
  • You have access
    Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s).
    S el Mansouri, M Tod, M Leclerq, O Petitjean, G Perret and M Porthault
    Drug Metabolism and Disposition February 1995, 23 (2) 227-231;
  • You have access
    Metabolism and elimination of oxazepam in F344 rats.
    R J Griffin and L T Burka
    Drug Metabolism and Disposition February 1995, 23 (2) 232-239;
  • You have access
    Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis.
    M Piquette-Miller and F Jamali
    Drug Metabolism and Disposition February 1995, 23 (2) 240-245;
  • You have access
    Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of inflammatory bowel diseases.
    Z C Liu, R A McClelland and J P Uetrecht
    Drug Metabolism and Disposition February 1995, 23 (2) 246-250;
  • You have access
    Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver.
    S E Clarke, A W Harrell and R J Chenery
    Drug Metabolism and Disposition February 1995, 23 (2) 251-254;
  • You have access
    Benzoic acid glycine conjugation in the isolated perfused rat kidney.
    K Poon and K S Pang
    Drug Metabolism and Disposition February 1995, 23 (2) 255-260;
  • You have access
    Oxidation of tolualdehydes to toluic acids catalyzed by cytochrome P450-dependent aldehyde oxygenase in the mouse liver.
    K Watanabe, T Matsunaga, I Yamamoto and H Yashimura
    Drug Metabolism and Disposition February 1995, 23 (2) 261-265;
  • You have access
    Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
    S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
    Drug Metabolism and Disposition February 1995, 23 (2) 266-270;
  • You have access
    Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6.
    E M Laurenzana, S L Sorrels and S M Owens
    Drug Metabolism and Disposition February 1995, 23 (2) 271-278;
  • You have access
    Contribution of the small intestine to the first-pass uptake and systemic clearance of propranolol in rabbits.
    P Du Souich, H Maurice and L Héroux
    Drug Metabolism and Disposition February 1995, 23 (2) 279-284;
  • You have access
    Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
    C H Yun, H S Lee, H Lee, J K Rho, H G Jeong and F P Guengerich
    Drug Metabolism and Disposition February 1995, 23 (2) 285-289;
  • You have access
    Contribution of oxidation and deacetylation to the bioactivation of acetaminophen in vitro in liver and kidney from male and female Sprague-Dawley rats.
    C A Mugford and J B Tarloff
    Drug Metabolism and Disposition February 1995, 23 (2) 290-294;
  • You have access
    Comparison of acetyl coenzyme A:arylamine N-acetyltransferase activity in the liver, kidney, and intestine of male and female rats from three strains.
    J A Ware, P Divakaruni and C K Svensson
    Drug Metabolism and Disposition February 1995, 23 (2) 295-297;
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition
Vol. 23, Issue 2
1 Feb 1995
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics